News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference


3/1/2012 10:41:02 AM

SAN DIEGO, March 1, 2012 /PRNewswire/ -- Receptos Inc. today announced that the company is scheduled to present at the Cowen and Company 32nd Annual Health Care Conference at noon EST on Wednesday, March 7, 2012, at the Boston Marriott Copley Place in Boston, Massachusetts. Faheem Hasnain, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs.

"This is an exciting time at Receptos as we move forward with plans to initiate multiple Phase 2 clinical trials later this year and to close our Series B financing round," Hasnain said. "This presentation at the Cowen and Company Health Care Conference gives us the opportunity to provide an update about these initiatives, as well as other areas of focus for Receptos."

About RPC1063 and S1P1 Agonists
RPC1063, developed in the labs of Receptos, is a novel, highly selective S1P1 agonist exhibiting picomolar potency that is effective in rodent models of multiple sclerosis, and possesses an excellent safety profile in non-clinical toxicology studies. In addition to selectivity, which reduces the likelihood of "off-target" side effects, RPC1063 has an appropriately short half-life to promote rapid reversibility of lymphopenia. S1P1 is a G protein-coupled receptor (GPCR) that binds the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P is a circulating lipid that binds to five GPCRs termed S1P1-5. S1P1 selectively regulates physiological functions in the immune and cardiovascular systems, including immune cell trafficking and the maintenance of endothelial integrity. In the disease state of multiple sclerosis, S1P1 agonism works by selectively sequestering circulating lymphocytes, blunting the underlying autoimmune cause of multiple sclerosis.

About Receptos
Receptos is a biopharmaceutical company developing autoimmune therapeutic candidates through informationdriven drug discovery, including GPCR structure determination. The company's lead program is a bestinclass S1P1 small molecule agonist candidate for autoimmune indications, including multiple sclerosis and inflammatory bowel disease, which will complete a Phase 1 clinical study in the first quarter of 2012. The S1P1 program is supported by the company's proprietary high resolution protein crystal structure of the S1P1 receptor. Receptos has established partnerships for its GPCR structure determination technology platform with Eli Lilly, Ono Pharmaceutical and Janssen Pharmaceuticals, Inc. For more information visit www.receptos.com.

Media and Investor Contacts:
Russo Partners
Ian Stone or David Schull (media)
(619) 308-6541 or (212) 845-4271
Ian.stone@russopartnersllc.com
David.schull@russopartnersllc.com

Cindy McGee (investors)
(619) 308-6538
Cindy.mcgee@russopartnersllc.com

SOURCE Receptos Inc.


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES